Compass Therapeutics, Inc. (NASDAQ:CMPX) Sees Significant Decrease in Short Interest

Compass Therapeutics, Inc. (NASDAQ:CMPX) was the recipient of a significant decrease in short interest in the month of May. As of May 31st, there was short interest totalling 1,550,000 shares, a decrease of 5.5% from the May 15th total of 1,640,000 shares. Based on an average daily trading volume, of 308,500 shares, the short-interest ratio is presently 5.0 days. Currently, 1.8% of the shares of the company are short sold.

Institutional Trading of Compass Therapeutics

A number of institutional investors have recently modified their holdings of CMPX. Opaleye Management Inc. acquired a new position in Compass Therapeutics in the first quarter valued at about $6,277,000. CM Management LLC increased its holdings in Compass Therapeutics by 148.0% in the 1st quarter. CM Management LLC now owns 310,000 shares of the company’s stock valued at $614,000 after buying an additional 185,000 shares during the period. Vanguard Group Inc. raised its position in shares of Compass Therapeutics by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 4,152,197 shares of the company’s stock valued at $8,221,000 after buying an additional 71,008 shares in the last quarter. Bleakley Financial Group LLC bought a new stake in shares of Compass Therapeutics during the 1st quarter worth approximately $80,000. Finally, Simplicity Wealth LLC acquired a new stake in shares of Compass Therapeutics during the 1st quarter worth approximately $80,000. 68.43% of the stock is currently owned by institutional investors.

Compass Therapeutics Trading Up 5.4 %

CMPX stock opened at $1.17 on Tuesday. Compass Therapeutics has a fifty-two week low of $1.06 and a fifty-two week high of $3.45. The business’s fifty day moving average price is $1.48 and its two-hundred day moving average price is $1.63.

Compass Therapeutics (NASDAQ:CMPX) last announced its earnings results on Monday, May 13th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03. Equities analysts predict that Compass Therapeutics will post -0.39 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Wedbush reaffirmed an “outperform” rating and set a $8.00 price target on shares of Compass Therapeutics in a report on Friday, March 22nd. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Compass Therapeutics in a research note on Monday, June 3rd.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.